SCHEMBL20927239

SCHEMBL20927239

CCC(=O)N1CCC(CC(=O)N2CCC(O)C2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.47
EPHX2 P34913 3/20 0.39
CHRNB2 P17787 3/20 0.39
CHRNA3 P32297 3/20 0.39
CHRNA4 P43681 3/20 0.39
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39
ADAM10 O14672 1/20 0.38
ERBB2 P04626 1/20 0.38
MMP2 P08253 1/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA7 P36544 2/20 0.38
EPHX1 P07099 1/20 0.37
DPP7 Q9UHL4 2/20 0.37
NAMPT P43490 1/20 0.36
TACR3 P29371 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TPSAB1 Q15661 1/20 0.35
TPSD1 Q9BZJ3 1/20 0.35
TPSG1 Q9NRR2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272430 0.88 DPP4 (0.51) DPP4EPHX2CHRNB2CHRNA3CHRNA4
SCHEMBL322192 0.88 DPP4 (0.51) DPP4EPHX2CHRNB2CHRNA3CHRNA4
SCHEMBL322191 0.88 DPP4 (0.51) DPP4EPHX2CHRNB2CHRNA3CHRNA4
SCHEMBL15874471 0.81 TACR3 (0.42) EPHX2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL15874470 0.81 TACR3 (0.42) EPHX2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL25633195 0.79 CHRNB2 (0.46) EPHX2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL16015437 0.79 CHRNB2 (0.46) EPHX2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL16621835 0.78 CHRNB2 (0.44) EPHX2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL10305115 0.78 CHRNB2 (0.44) EPHX2CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL10305071 0.78 MEN1 (0.47) DPP4EPHX2CHRNB2CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 DPP4 2073/4885EPHX2 1771/4885CHRNB2 3991/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 DPP4 2073/4885EPHX2 1771/4885CHRNB2 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.